Trump to Sign Order Reducing Drug Prices in US
Trump to sign an executive order cutting US prescription drug prices by up to 80%.
- President Trump to implement a significant drug pricing policy change.
- Order aims to cut drug prices by up to 80%.
- Medicare pricing will align with the lowest global prices.
President Donald Trump announced plans to sign an executive order on May 12, 2025, at the White House to cut US prescription drug prices significantly.
Trump’s executive order to cut drug prices could dramatically reduce healthcare costs, marking a pivotal move in US healthcare economics.
The order focuses on implementing a “Most Favored Nation policy that ties Medicare drug prices to the lowest international rates. This is not a new initiative, as Trump had attempted similar measures during his previous term.
Key figures include President Trump and Health Secretary Robert F. Kennedy Jr., who negotiated with pharmaceutical companies. The order directs the Department of Health and Human Services to modify Medicare payment structures.
This policy is expected to immediately cut drug prices for American consumers, potentially saving billions nationwide. It targets pharmaceutical companies that have charged higher US prices, often justified by research and development costs.
The economic impact could be profound, changing the competitive landscape of the pharmaceutical industry. Healthcare costs could see reductions not experienced before, ushering a shift in market dynamics.
If successful, this could set a precedent for future healthcare reforms. The focus remains on addressing consumer affordability and market fairness in drug pricing.
Experts observe that if implemented, this could disrupt the pricing model of pharmaceutical companies, previously justified by high development costs. “Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before,” emphasized President Trump.
More From Crypto News
Intel, Oracle and IBM Object to OKX–ICE Tokenized Stock Plans
Intel, Oracle, IBM and IonQ have formally objected to the OKX–ICE tokenized stock plans, according to an October 26 public notice published by OKXICE — the join...
Ark Invest Buys Circle Shares, Sells Bitcoin ETF as BTC Falls
The two moves point in opposite directions within the crypto-linked investment space. Ark added exposure to Circle, the USD Coin issuer and stablecoin infrastru...
Ripple Approved to Operate as a U.S. National Trust Bank
A national trust bank is a federally chartered institution authorized to provide trust and fiduciary services, including asset custody, without engaging in comm...
Ethereum Foundation’s Latest ETH Sale Draws Criticism
The Ethereum Foundation has drawn fresh criticism following its latest sale of ETH, with observers describing the timing and communication around the transactio...
Strategy Pauses Bitcoin Buys as STRC Buybacks Continue
Strategy’s latest weekly update showed no new Bitcoin purchase reported, while the company continued repurchasing shares of its STRC preferred stock. The diverg...
Bitcoin Tests $80K as $550M Crypto Liquidations Hit
Bitcoin is testing the $80,000 support level as reports of roughly $550 million in crypto liquidations circulate across market data platforms. Whether BTC can h...
